GREENVILLE, N.C. — Mayne Pharma Inc. has rolled out Fabior Foam 0.1%, an acne treatment, and Sorilux Foam 0.005%, a psoriasis treatment, in the United States.

Launched by the Mayne Pharma Specialty Brands division, Fabior and Sorilux foam previously were marketed by GlaxoSmithKline. Mayne acquired the two products in August 2016.

Mayne said Fabior and Sorilux complement its acne medication Doryx, the first branded product launched by the company’s specialty division in the U.S. in May 2015.

“Fabior and Sorilux are a great strategic fit with the existing Doryx franchise and participate in attractive and growing markets,” Mayne Pharma chief executive officer Scott Richards stated. “Both products are well-differentiated with compelling clinical data that physicians and patients will appreciate.

“The foam delivery platform has a well-established reputation with dermatologists due to ease of application, especially in hair-bearing areas and under clothing,” Richards noted. “With a focused and sustained marketing effort, we can further support the needs of patients and dermatologists, and these products will become important treatment options for people with acne and plaque psoriasis.”

Fabior Foam (tazarotene) is indicated for the topical treatment of acne and is part of the single active retinoid market, in which 5 million prescriptions are written annually, according to Mayne. The company noted that this market is much larger than the oral antibiotic acne market that includes Doryx, since topical products are used more frequently by acne patients, ranging from mild and moderate to severe acne cases.

Used for the topical treatment of plaque psoriasis of the scalp and body, Sorilux Foam (calcipotriene) is part of the single active vitamin D market, in which 0.5 million prescriptions are written annually, Mayne said.

“We have met our planned commercial launch timing and have also now internalized our 60-person dermatology sales team from a third-party contract sales organization, which is expected to provide cost savings, improved ability to attract and retain talent, improved performance management and, ultimately, improved sales force effectiveness,” Richards added. “Over time, we expect to commercialize complementary product innovations in dermatology and other specialty therapeutic areas utilizing the company’s internal pipeline or via targeted in-licensing and/or product acquisitions.”